Fosun Kite Biotechnology Co., Ltd.

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first three quarters of 2024. From January to September 2024, Fosun Pharma achieved revenue of RMB30.91 billion, an increase of about 5.74% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.84 billion, up by 24.58% YoY. In 2024, Fosun Pharma will further focus on innovative drugs and high-value devices, and continue to promote lean operations, cost reduction, efficiency improvement, and asset rationalization to optimize assets and financial structure, actively promote supply chain management and operational efficiency, and achieve healthy operating cash flow. In the first three quarters of 2024, the net cash flow from operating activities of Fosun Pharma was RMB2.99 billion, a year-on-year increase of 21.33%; the management expense ratio decreased by 0.15 percentage points YoY; excluding the impact of newly acquired companies, management expenses decreased by approximately RMB300 million on the same basis. Focusing on advantageous therapeutic areas with innovative R&D pipelines continue to advance In terms of innovative R&D, Fosun Pharma continues to focus on advantageous pipelines to achieve efficient results and continuous implementation of innovative products. In the first three quarters of 2024, Fosun Pharma's R&D expenditure totaled RMB3.92 billion. In particular, R&D expenses were RMB2.65 billion. In addition to independent R&D, the Group fully implemented an open R&D model, and incubated and invested in R&D projects by initiating/managing industrial funds and other diversified ways, so as to ensure the sustainability of innovation and R&D. Fosun Pharma's innovative drug business mainly covers the core therapeutic areas of solid tumors, hematological tumors and immuno-inflammatory diseases, with emphasis on the enhancement of the core technology platforms of antibody/ADCs, cellular therapy and small molecules, to create an open and global innovative R&D system, continuously enhance pipeline value, and promote the development and commercialization of its products. In the field of tumor immunotherapy, on September 13, 2024, Fosun Pharma announced it will acquire the 50% stake in Fosun Kite and will wholly own Fosun Kite (now renamed as "Fosun Kairos"). In the future, Fosun Kairos will serve as the core platform of Fosun Pharma's cell therapy, continue to focus on the field of tumor immunotherapy, as well as to promote the development and commercialization of existing licensed products, Axi-Cel (i.e. Fosun Kite's marketed product "Yi Kai Da") and Brexu-Cel (i.e. Fosun Kite's pipeline project FKC889), in Chinese mainland, Hong Kong SAR and Macau SAR with Kite Pharma. In the third quarter of 2024, Fosun Pharma's multiple independently developed innovative products and pipeline clinical trial results were announced in industry conferences and journals, further consolidating its dominant position in the fields of hematological tumors, breast cancer, lung cancer and other tumors. Particularly, the interim analysis results of the Phase III study of Foritinib Succinate (SAF-189s), an innovative drug independently developed to treat ALK-positiveb advanced non-small cell lung cancer (NSCLC), were released during the 2024 World Conference on Lung Cancer ("WCLC"). The above-mentioned studies have found that the overall efficacy of Foritinib Succinate is good. Compared with crizotinib treatment, it can significantly improve PFS and reduce the risk of CNS progression. Its safety is controllable, and no new safety signals appeared after treatment. Faritinib Succinate is expected to break through the current clinical difficulties faced in the treatment of ALK-positive NSCLC and bring new treatment options to NSCLC patients. The multicenter real-world study of Fosun Pharma's self-developed serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer was released at the 2024 WCLC. The ASTRUM-005R study provides additional empirical evidence to support the therapeutic value of serplulimab plus chemotherapy and complements the pivotal data from the ASTRUM-005 clinical trial. Additionally, during the reporting period, the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency (EMA) issued a positive opinion recommending approval for Fosun Pharma's self-developed serplulimab injection in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). The CHMP's opinion will be submitted to the European Commission (EC) as a reference for marketing authorization approval. Results of the phase 2 study of HLX22, an innovative anti-HER2 monoclonal antibody (mAb), in combination with Han Qu You (trastuzumab) and chemotherapy for the first-line treatment of HER2-positive advanced gastric/gastroesophageal junction (G/GEJ) cancer were presented on 2024 ESMO Gastrointestinal Cancers Congress (ESMO GI) and MED, a flagship clinical and translational research monthly journal by Cell Press. The results showed that add HLX22 to HLX02 (trastuzumab) and chemotherapy as first-line therapy improved efficacy in HER2-positive G/GEJ cancer patients with manageable safety. In September 2024, Fosun Pharma announced the Biologics License Application ("BLA") for the licensed product RT002 (DaxibotulinumtoxinA-lanm, Chinese trademark: 达希斐®) for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients, was approved by the National Medical Products Administration ("NMPA"), becoming the first DaxibotulinumtoxinA-lanm approved for marketing in Chinese mainland. Additionally, the results of a Phase III multicenter, double-blind, placebo-controlled study conducted in China for the treatment of moderate to severe glabellar lines were published in the Journal of Plastic, Reconstructive & Aesthetic Surgery (JPRAS). The study demonstrates that the product provides durable efficacy and high safety in Chinese patients with moderate to severe glabellar lines. Actively implementing share repurchases and increasing holdings with continuous efforts on enhancing ESG Fosun Pharma, a company listed on both the A-share and H-share markets, and its controlling shareholder Fosun High Tech have actively engaged in share repurchases and increased holdings this year, demonstrating confidence in the Company's future development and further boosting market confidence. In the first three quarters of 2024, Fosun Pharma spent approximately RMB127 million and approximately HKD66.9 million to repurchase around 5.68 million A shares and 5.47 million H shares respectively. As of now, the H Share Repurchase Plan is still valid. In addition, the controlling shareholder Fosun High Tech, has spent a total of approximately RMB101 million to increase its holdings of around 4.30 million A shares of Fosun Pharma, under the latest Shareholding Increase Plan. Founded in 1994 and with three decades of development, Fosun Pharma has grown into a global innovation-driven pharmaceutical and healthcare industry group. The Company always regards innovation as its primary social responsibility, consistently focusing on unmet clinical needs, prioritizing innovative R&D, advancing the launch of innovative products, promoting drug accessibility and affordability, and driving high-quality corporate growth. Fosun Pharma maintained an A grade rating in MSCI ESG Ratings for three consecutive years and an A- rating in HSI ESG, ranking among the top tier in the healthcare industry for pharmaceuticals and biotechnology. It was also selected as a constituent of the Hang Seng (China A) Corporate Sustainability Benchmark Index ("HSCASUSB"), Hang Seng (China A) Corporate Sustainability Index ("HSCASUS"), and Hang Seng (Mainland and HK) Corporate Sustainability Index ("HSMHSUS"). With its sustained excellence in innovation and global operational capabilities, Fosun Pharma has been recognized by multiple authoritative institutions in innovative R&D, ESG and other areas. The Company ranked in the top four of China's 2023 Top 100 Pharmaceutical Industry, was included in the "China Best Managed Companies" List (BMC) for the second consecutive year and was listed in Forbes 2024 China ESG 50. In addition, the Company has actively introduced its independently developed artemisinin-based innovative products to Africa, providing a Chinese solution to the global fight against malaria. This initiative highlights the inclusive, diverse, and open nature of ESG and earned Fosun Pharma recognition as an "Inspirational ESG Case", serving as a model for corporate ESG practices. *** About Fosun Pharma Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma's innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules. Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of "Innovation for Good Health", continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation. For more information, please visit the official website: SOURCE Fosun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

随着系列产业政策和金融资金支持政策陆续出台，深圳市光明区生物医药产业规模正不断壮大。 作为助力这一目标的重要抓手，10月21日，“第二届国际生物科技创新与投资大会”在深圳市光明云谷国际会议中心正式启幕。 本届大会由中国外商投资企业协会、深圳市光明区人民政府主办，中国外商投资企业协会生物科技创新工作委员会、中国外商投资企业协会金融与投资工作委员会、中国外商投资企业协会科技创新与产业促进工作委员会、深圳市卫光生命科技控股集团有限公司与同写意共同承办，默克生命科学协办。 基于“共建创新生态 共赢产业未来”的主题，本届大会聚焦生物医药出海与国际化创新、创新药投融资、医疗器械等产业发展风向标，旨在打造集政、产、学、研、金、媒为一体的生物医药交流发布、成果展示、创新合作平台。 除了主旨会议外，10月21-22日大会期间，医药、医疗器械、动物保健、创新技术、生物工艺、体外诊断等六个主题分会也陆续举办。 花絮视频 领导致辞 原高强 中国外商投资企业协会副会长 当前，全球生物医药产业正处于快速发展的重要时期， 新技术、新业态、新模式层出不穷，中国也呈现出蓬勃发展的态势，政府高度重视，出台了一系列支持政策。在这样的背景下，中国外商投资企业协会积极发挥桥梁纽带作用，致力于促进国内外生物医药的交流合作，推动生物医药产业国际化进程。本次大会的举办，正是协会积极履行职责、服务企业发展的重要举措之一。未来，我们将继续推动产业的发展。 ∨ 姚高科 光明区委常委、常务副区长 去年，首届国际生物科技创新与投资大会在光明区成功举办，会上共同发起成立国际生物科技联合创新中心。今天，我们在此举办第二届大会。经过一整年的努力拼搏，光明区生命科学领域在创新载体、产业发展、人才集聚、金融支持、城市配套等方面都取得了长足发展。一直以来，国家高度重视对外开放，此次大会正是落实中央决策指引，紧密对接外商外资，加快推动与国际生物医药企业战略合作的重要举措。本次活动集聚了众多国内外的院士专家、企业高管、研究学者，希望大家畅所欲言，为光明区生物医药产业发展提供新思路、新动能。 主旨报告 刘国恩 北京大学国家发展研究院博雅特聘教授 北京大学全球健康发展研究院院长 医药创新的经济学思考 卫生健康在现代经济中的地位非常重要。在此背景下，医药创新就相当于火车头，是重中之重。而如何创新，美国的做法仍有很大参考意义。美国联邦政府每年在基础医学科研上投入将近财政收入的1%，专利制度赋予创新药在专利期的独有定价权。更重要的是，这整套设计解放了社会创新思想，最终成就美国医药创新的高地。 ∨ 朱迅 同写意新药英才俱乐部创始理事长 对未来中国创新药开发趋势的研判 未来十年，中国将完成医药产业的全方位的重构：医保模式、DRG、ICH、药监接轨国际法规体系，制药行业商业模式转换完成；商业模式变化将重塑制药公司的格局，全能型大公司及特色性小公司的优势突显；药品低门槛时代结束，各细分领域的竞争加剧，并形成集聚态势。 ∨ 张丹 俄罗斯工程院外籍院士 谱新生物联合创始人兼联席董事长 对标国际市场的先进治疗开发策略 CAR-T、TCR-T等基因修饰T细胞疗法，正在抗肿瘤领域显示出巨大潜力。但部分挑战在于，安全性问题、产品复杂性等因素制约新药从实验室迅速走向临床。FDA及我国相关机构监管的灵活性，提供了助力产业发展的可参考经验。 ∨ 陈有海 欧洲人文和自然科学院院士 美国医学与生物工程院院士 深圳理工大学药学院院长 大湾区生物医药产业发展路径 目前，虽然美欧日生物医药产业仍处于全球产业链主导地位，但中国是资源大国、医药大国，在一些新兴生物医药领域已经达到甚至超过许多其他国家的水平。得益于中国生物经济时代发展面临重大机遇，大湾区生物医药产业只有敢为天下先，才能走上创新高质量发展路径。 ∨ 陈冰 阿斯利康国际业务拓展合作与战略投资副总裁 跨国药企如何支持中国创新-阿斯利康的探索 阿斯利康长期深耕中国，赋能本土创新。2023年以来，阿斯利康已与10家中国创新药企达成全球授权合作，覆盖肿瘤、心血管代谢等疾病领域，累计总金额超85亿美元。通过内生和外延创新并举，阿斯利康将继续立足中国面向全球，推动更多创新疗法的开发。 ∨ 朱和丰 凯雷资本高级顾问 光辉国际管理合伙人 生物医药的挑战与未来 中国医药行业的现状与挑战，一方面是外资企业发展停滞，另一方面是新兴初创企业面临瓶颈。而中国医药行业的未来，需要药企从创新1.0升级迈向2.0，深耕本土和国际市场；与此同时，也有赖于政策引导优化行业环境，吸引外企，国际和本土资本市场的持续投资。 圆桌对话 朱和丰（主持）：凯雷资本高级顾问，光辉国际管理合伙人 周　勤：阿尔法西格玛总经理 刘　畅：勃林格殷格翰大中华区健康事务与市场准入副总裁 樊　琳：药明巨诺副总裁，市场准入与创新支付负责人 胡瑞连：睿智医药董事长兼CEO 罗　飞：松禾资本创始合伙人 - 中国新药未来之路 - • 从产业投资节奏上看，中国新药领域已走过第一个阶段，大约是2015年到2022年。这个时期的快速发展，得益于三个红利，即海归科学家等人才回流、科创板等二级资本市场放开、一致性评价等监管改革。这些红利都会有相对的高点，所以出现回调也有是正常情况。 • 消极者正确，积极者前行。目前经济环境确实面临不小压力，有人认为是资本寒冬，但也会有人继续扎进生物医药创新。背后的出发点，就是在于相信这个行业，对赛道有信心，肯付出。只有这样，才能带领团队走出低谷。 • 外资大药厂与内资Biotech间存在不少差别，但现阶段本土创新药企对人才的需求，也在与时俱进，同样需要海归提供足够的专业眼光，针对本土政策环境，为赋能公司。此外，对于进入国内Biotech的人才，在融入团队、情商等方面往往提出更高的要求。 • 创新不单单是考验企业的能力。作为一个重监管的行业，医药领域的发展升级也离不开政策监管方的支持，无论是从鼓励研发、保护专利还是在市场定价上，创新都需要不同类型的参与者合作推动。 • 尽管中国生物医药产业存在许多挑战，但毕竟作为全球第二大市场，仍值得国内外公司投入。作为Biotech，在顺境是可以安心成为小而美的公司，但在逆境下，更需要创新变革。本质上，未来会是对优秀人才的竞争。 园区推介 陈晓青 光明区科技创新局局长 锚定“世界一流科学城”这一发展目标，光明区正在打造原始创新策源地、科研经济先行地、创新人才集聚地，加快构建生物医药从原始创新、研发、转化、制造到应用的完整生态体系，为深圳市生物医药产业高质量发展注入新动能。 揭牌仪式 光明区持续推动企业与高校、科研机构等之间的合作与交流，助力中国企业走向世界舞台，提升国际竞争力和影响力。大会现场，在与会领导嘉宾的见证下，举行了两场重要揭牌仪式。 Part.01 中国外商投资企业协会科技创新与产业促进工作委员会外籍院士成果转化办公室揭牌仪式 Part.02 深圳理工大学细胞与基因技术研究院揭牌仪式 合作签约 光明区重点围绕生命、信息、材料三大领域，集中布局9个重大科技基础设施，N个前沿交叉平台，2个广东省实验室和2所研究型高校，集聚了各领域高层次人才。基于此背景，四场合作签约仪式在大会开幕式环节圆满举行。 Part.01 医学转化创新研究院战略合作签约仪式 Part.02 深圳赛桥生物创新技术有限公司与复星凯特生物科技有限公司合作签约仪式 Part.03 卫光控股、卫光生物等项目战略合作签约仪式 Part.04 光明区科技创新局战略合作签约仪式 分会一 医药创新与投融资 中国创新药行业正从“引进”向“输出”转变。通过加大研发投入、推动技术升级，国内药企正在加速布局海外市场。 论坛现场，嘉宾们对于出海路径分享，为更多后来者提供启发。另一些与会嘉宾，则强调了借助NewCo模式和对外授权合作等方式实现产品国际化的重要性。 台上嘉宾们讨论了中国生物医药产业创新与投资的新格局。他们一致认为，除了mRNA等技术进步外，创新与资本的良性循环，加之市场需求的增长，都会刺激中国生物医药产业迎来更多的投资机会和创新突破。 分会二 医疗器械与医工转化 分会协办：奥咨达医疗器械产业集团、齐创新思数字健康技术联盟 医疗器械与医工转化是当前我国医疗产业创新发展的重要方向。主题分会现场，来自学术、产业等不同领域等专家学者，对此进行深入讨论。 医疗器械的创新历程是科研与临床相互印证、医学与工程交相融合的历程。这种融合不仅提升医疗器械的研发效率，还提高产品的临床应用价值。而AI、数字化的加入，也有望进一步给医疗器械产业带来深刻变革。 不过，需要看到，医工转化还面临一些挑战，例如对复合型人才的高要求。以临床需求为导向，开展充分的分工合作，可以有效减小创新风险。 分会三 动物保健产业专题会 动物保健市场正在快速增长。调研机构预计，到2030年，该产业的规模或将突破至750亿美元。行业加速变革前夕，具备研发创新基因的企业将持续进击。 包括宠物领养数量增加、肉类和乳制品消费增加、人畜共患疾病发病率上升等现实需求，以及技术进步和更先进疗法的研发，都会进一步推动行业生态的持续改善和发展。 会议现场，与会领导、嘉宾就深圳市光明区动保产业的成就与挑战，以及中国加入VICH等话题，展开了深度交流。与会者一致认为，“后疫情”时代，全球动物保健产业需要加强合作，共同促进人与动物福利的提高。 大会花絮 同写意会务团队 END 相关阅读 （上下滑动查看更多） • 写意现场 | 生物药开发与生产实战研修班（烟台站）圆满落幕 • 现场 | 2024同写意医美与器械创新前沿华西论坛成功举办 • 现场 | 第八届全国核酸疫苗大会圆满落幕 • 现场 | 重磅打造！同写意CGT年度品牌大会圆满落幕 • T20现场丨金鸡湖畔同写意，饕餮盛宴共享之 • T20现场丨中国医药创新路在何方？让历史告诉未来 • T20现场丨同写意20周年庆典晚会 • 现场丨百位新药创始人研讨全链条支持医药产业创新发展政策 • 现场 | 聚焦创新工艺，成就医药产业未来 • 现场｜烟花三月下扬州，打造生物医药新质生产力 • 现场｜万物皆可偶联，见证XDC无限可能 • 现场｜天府盛宴，花重锦城，XDC产业乘风而起 • 现场 | 修内功，练招式，2024全球创新药技术交易论坛圆满落幕 • 现场丨用新兴生物技术，赋能万亿生命健康 • 现场｜健康无止境，抗衰有未来 • 长三角医药创新发展联盟两周年工作会议暨2023'长三角首届生物医药产业链关键技术研讨及供需对接会议在沪成功举办 • 现场｜聚焦GLP-1分离纯化，助力本土多肽药物发展 • 现场丨共建医药高地，探索保税机遇，生物医药未来大兴论坛圆满收官 • 现场 | 第四届国际老化与疾病大会落幕，下一次香港见！ • 现场｜全球老化与疾病研究顶尖科学家齐聚张江科学会堂 • 现场｜如何把握药品政策，开发未来临床需求新药？ • 权威解读！药品政策助推生物医药产业高质量发展 • 现场丨千人盛会，见证药品政策助推产业高质量发展 • 现场丨共襄医药盛会，洞见创新未来，首届北京创新药CMC论坛圆满收官 • 现场 | 诗画剡溪，肽美嵊州，多肽药物正启航 • 现场 | 浙江 · 嵊州多肽产业发展大会暨生物医药创新人才交流大会开幕！ • 现场 | 引技术源泉，品转化成果，首届（北京）细胞制药产业大会圆满收官 • 现场｜在青浦，同康桥，共写意：新基建，新未来 • 从百亿向万亿市场进发，问道本土药企的未来大健康产业机遇 • 现场丨跨界融合，深向未来，2023 BT大会圆满收官 • 2023深圳国际生物医药产业创新发展大会：跨界融合 深向未来 • 现场｜50位产业领袖深圳来见，共话生物医药的“敢为人先” • 现场丨金鸡湖再摆21桌前沿技术“满汉全席”，医药人再享受源头创新“饕餮盛宴” • 现场丨让前沿技术，为中国医药创新注入源头活水 • 现场丨200家创新药机构首脑来了，中国生物制药创新链盟成立！ • 现场丨六大论坛聚焦生物制药前沿，首届广州国际生物医药产业大会落幕 • 现场丨打造湾区硬核产业链，共创广州医药新格局

编者按 为深入贯彻落实党中央国务院、市委市政府关于建设制造强国、质量强国、推动高质量发展的决策部署，推进实施制造业卓越质量工程，实现产品高质量、企业现代化、产业高端化，市经济信息化委在全市范围内持续组织开展“质量标杆”活动。我们将专题介绍和分享2023-2024年度上海市“质量标杆”先进案例，促进先进质量管理方法和实践的推广，推动企业建立先进质量管理体系，提升制造业质量效益和核心竞争力，加快新型工业化进程。 复星凯特生物科技有限公司（简称“复星凯特”）是国内领先的细胞免疫治疗企业，专注于CAR-T药品的研发、产业化和商业化发展，公司生产的CAR-T药品阿基仑赛注射液是我国首个获批上市的细胞治疗药品。 区别于传统药物，CAR-T细胞疗法是高度个人定制化的药品，每位接受治疗的患者都要进行全流程管理，包括单采血、冷链运输、细胞制备、质检、放行、深冷运输、复融、回输。这种“血管到血管”的独特流通方式对药品的生产和质量管控带来了巨大的挑战。 针对CAR-T的特殊性，复星凯特以“质始质终，将质量融入每一个细胞”为质量战略方针，搭建了覆盖制造端、物流端、医院端的高标准CAR-T全流程质量管理和守护体系。 复星凯特CAR-T全流程质量管理和守护体系 制造端：打造世界一流细胞治疗产品质量管理。复星凯特严格遵循国内外药品、无菌药品、血液制品、细胞治疗产品等GMP法规，搭建起涵盖质量手册、工艺规程/质量标准、标准管理规程、标准操作规程的4层级GxP质量管理体系，保障CAR-T药品生产的各环节各流程的操作规范化标准化，始终确保产品质量。同时，全方位加强质量能力建设，打造生产质量和实验室质量人才矩阵，建设卓越质量文化，全方位推动质量目标的实现。 物流端：鉴别链（COI）/管控链（COC）双链全流程追溯。复星凯特建立了一套覆盖单采血、血样运输、中心化生产、终产品运输、复融回输全流程的双向追溯质量监管系统，即鉴别链（COI）/管控链（COC）。系统对患者进行伪名化，每个患者的一次单采对应一个唯一追溯码，并与相应的供体材料识别号、自体CAR-T药品批号进行关联，确保在供体材料接收、自体CAR-T药品流通、交付、使用过程中，不会发生混淆、差错。系统也通过唯一追溯码对订单流程中的每一个步骤和环节进行核对确认，实现对自体CAR-T药品生产、运输、使用全过程的数据实时收集和质量管理。  复星凯特COI鉴别链/COC管控链追溯系统 医院端：实施 CAR-T治疗中心准入管理与动态维护机制。作为国内少数成功实现CAR-T药品产业化及商业化的企业，复星凯特率先建立了一套严格的CAR-T治疗中心准入管理和动态维护体系，对医院单采、复融、输注、MDT（多学科治疗）等CAR-T诊疗各环节以及人员管理、文件管理进行全面评估考察。复星凯特还组建了一支专业的CAR-T运营专员团队，为患者提供全程的专属服务。 得益于该经验的良好实践，复星凯特2023年产品商业化生产制备成功率超过90%，高于国际平均水平，冷链运输全程“零差错”，市场占有率持续领先，惠及700余位国内淋巴瘤患者。 来源：上海经信委 点击“阅读原文”查看